AmericanHHM

National Surgical Centers Stockton Adds FDA-Approved Procedure to Relieve Painful Diabetic Neuropathy

Wednesday, May 10, 2023


National Surgical Centers Stockton (NSC Stockton), an outpatient surgery center, is now offering high-frequency spinal cord stimulation (SCS) procedure(s) for the treatment of painful diabetic neuropathy (PDN). The technology, called HFX, is made by medical device company NEVRO of Redwood City, Calif. HFX is an FDA-approved, non-drug treatment for PDN and is the only paresthesia-free therapy approved by the FDA to treat painful diabetic neuropathy (PDN) with unrivaled evidence-based outcomes.

"People with painful diabetic neuropathy know it to be a cruel addition to the chronic disease they must fight every day," said B.J. Sandhu, MD, Interventional Radiologist at National Surgical Centers Stockton. "HFX for PDN offers an effective option to alleviate this agonizing and persistent sensation. There is no other therapy that provides this level of pain relief while eliminating the tingling from paresthesia, and to offer it to people here in Stockton is an absolute privilege. I believe this can make a real difference for those suffering from PDN."

More than 34 million people in the U.S. have diabetes1, and it's estimated that 20-25% of people with diabetes will develop PDN.2 The condition is associated with a wide range of symptoms including pain in the limbs described as burning, freezing, stabbing, shooting, hypersensitivity or deep aching.3 Traditional treatment options for PDN include over-the-counter medications, prescription medications, physical therapy and injections, but for many people, these options are inadequate for long-term relief.

HFX for PDN is the only high-frequency paresthesia-free spinal cord stimulation system approved by the Food and Drug Administration (FDA) with a specific indication for PDN. Nevro HFX is a comprehensive solution that includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain. HFX for PDN means that a patient has been implanted with a Senza System and programmed to include a frequency of 10 kHz.

The Senza device is implanted during a quick and minimally invasive procedure, and then begins delivering mild pulses at a high frequency directly to the spinal cord to stop pain signals from reaching the brain. In a recent study, 92% of patients reported high satisfaction with the therapy.

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit